News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE): Adding Inspra(R) (eplerenone) To Standard Therapy Reduces The Incidence Of New Onset Atrial Fibrillation/Flutter (AF/F) In Patients With Systolic Heart Failure, Sub-Analysis Shows


5/23/2011 9:23:25 AM

Pfizer Inc. (NYSE: PFE) today announced results from a pre-specified sub-analysis1 of the EMPHASIS-HF trial2 which showed that Inspra® (eplerenone), added to standard recommended therapy, statistically significantly reduced the incidence of new onset atrial fibrillation or flutter (AF/F) in patients with systolic heart failure and mild symptoms, compared with placebo plus standard therapy. This analysis was a pre-specified secondary endpoint in the EMPHASIS-HF study, the results of which were presented to physicians attending the European Society of Cardiology Heart Failure Congress in Gothenburg, Sweden.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES